These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 34108941

  • 1. Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.
    Indirli R, Ferreira de Carvalho J, Cremaschi A, Mantovani B, Sala E, Serban AL, Locatelli M, Bertani G, Carosi G, Fiore G, Tariciotti L, Arosio M, Mantovani G, Ferrante E.
    Front Endocrinol (Lausanne); 2021; 12():689887. PubMed ID: 34108941
    [Abstract] [Full Text] [Related]

  • 2. Efficiency of Single Dose of Tolvaptan Treatment During the Triphasic Episode After Surgery for Craniopharyngioma.
    Gürbüz F, Taştan M, Turan İ, Yüksel B.
    J Clin Res Pediatr Endocrinol; 2019 May 28; 11(2):202-206. PubMed ID: 30257818
    [Abstract] [Full Text] [Related]

  • 3. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH, Bohm NM, Nemecek BD, Crawford R, Kelley D, Bhasin B, Nietert PJ, Velez JCQ.
    Am J Kidney Dis; 2018 Jun 28; 71(6):772-782. PubMed ID: 29478867
    [Abstract] [Full Text] [Related]

  • 4. Tolvaptan resistance is related with a short-term poor prognosis in patients with lung cancer and syndrome of inappropriate anti-diuresis.
    Lacquaniti A, Campo S, Russo A, Adamo V, Monardo P.
    G Ital Nefrol; 2023 Feb 27; 40(1):. PubMed ID: 36883921
    [Abstract] [Full Text] [Related]

  • 5. Factors predicting postoperative hyponatremia and efficacy of hyponatremia management strategies after more than 1000 pituitary operations.
    Jahangiri A, Wagner J, Tran MT, Miller LM, Tom MW, Kunwar S, Blevins L, Aghi MK.
    J Neurosurg; 2013 Dec 27; 119(6):1478-83. PubMed ID: 23971964
    [Abstract] [Full Text] [Related]

  • 6. Tolvaptan corrects hyponatremia and relieves the burden of fluid/dietary restriction and hospitalization in hyponatremic patients with terminal lung cancer: a report of two cases.
    Kai K, Tominaga N, Koitabashi K, Ichikawa D, Shibagaki Y.
    CEN Case Rep; 2019 May 27; 8(2):112-118. PubMed ID: 30637666
    [Abstract] [Full Text] [Related]

  • 7. Clinical Experience of the Efficacy and Safety of Low-dose Tolvaptan Therapy in a UK Tertiary Oncology Setting.
    Chatzimavridou-Grigoriadou V, Al-Othman S, Brabant G, Kyriacou A, King J, Blackhall F, Trainer PJ, Higham CE.
    J Clin Endocrinol Metab; 2021 Oct 21; 106(11):e4766-e4775. PubMed ID: 33693944
    [Abstract] [Full Text] [Related]

  • 8. Diagnosing and Treating the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Verbalis JG, Greenberg A, Burst V, Haymann JP, Johannsson G, Peri A, Poch E, Chiodo JA, Dave J.
    Am J Med; 2016 May 21; 129(5):537.e9-537.e23. PubMed ID: 26584969
    [Abstract] [Full Text] [Related]

  • 9. Tolvaptan treatment in hyponatremia due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH): effects on survival in patients with cancer.
    Bilgetekin I, Erturk I, Basal FB, Karacin C, Karadurmus N, Oksuzoglu B, Demirci U.
    Int Urol Nephrol; 2021 Feb 21; 53(2):301-307. PubMed ID: 32869173
    [Abstract] [Full Text] [Related]

  • 10. [Hyponatremia in older persons (II)-A clear treatment : How to detect tricks and avoid pitfalls].
    Hofmann W, Flägel K, Gosch M.
    Z Gerontol Geriatr; 2020 Aug 21; 53(5):463-472. PubMed ID: 32691149
    [Abstract] [Full Text] [Related]

  • 11. Strategies to reduce readmissions for hyponatremia after transsphenoidal surgery for pituitary adenomas.
    Deaver KE, Catel CP, Lillehei KO, Wierman ME, Kerr JM.
    Endocrine; 2018 Nov 21; 62(2):333-339. PubMed ID: 29961198
    [Abstract] [Full Text] [Related]

  • 12. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A, McCormick L, Rahman M.
    Adv Ther; 2021 Dec 21; 38(12):5721-5736. PubMed ID: 34693505
    [Abstract] [Full Text] [Related]

  • 13. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ, Ahmad F, Blais JD, Chiodo J, Zhou W, Glaser LA, Czerwiec FS.
    Cancer Med; 2017 Apr 21; 6(4):723-729. PubMed ID: 28251822
    [Abstract] [Full Text] [Related]

  • 14. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA, Cranston IC.
    BMC Endocr Disord; 2017 Nov 06; 17(1):69. PubMed ID: 29110656
    [Abstract] [Full Text] [Related]

  • 15. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P, Waung JA, Bagkeris E, Carr H, Khoo B, Cohen M, Bouloux PM.
    Clin Endocrinol (Oxf); 2016 Apr 06; 84(4):620-6. PubMed ID: 26385871
    [Abstract] [Full Text] [Related]

  • 16. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW, Yi JH, Kang KP, Kim HY, Kim SW, Choi HY, Ha SK, Kim GH, Kim YW, Jeong KH, Shin SK, Kim HJ.
    J Korean Med Sci; 2018 Apr 09; 33(15):e112. PubMed ID: 29629516
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin receptor antagonist in the treatment of the syndrome of inappropriate antidiuretic hormone in general hospital practice.
    Rajendran R, Grossman AB, Kar P.
    Endocr J; 2012 Apr 09; 59(10):903-9. PubMed ID: 22785335
    [Abstract] [Full Text] [Related]

  • 18. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S, Zhao JJ, Tong NW, Guo XH, Qiu MC, Yang GY, Liu ZM, Ma JH, Zhang ZW, Gu F.
    J Clin Pharmacol; 2014 Dec 09; 54(12):1362-7. PubMed ID: 24906029
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C, Robinson P, O'Reilly K, Lundberg J, Gisby M, Ländin M, Skov J, Trueman D.
    BMC Endocr Disord; 2016 May 16; 16(1):22. PubMed ID: 27184496
    [Abstract] [Full Text] [Related]

  • 20. Open-label, multicenter, dose-titration study to determine the efficacy and safety of tolvaptan in Japanese patients with hyponatremia secondary to syndrome of inappropriate secretion of antidiuretic hormone.
    Arima H, Goto K, Motozawa T, Mouri M, Watanabe R, Hirano T, Ishikawa SE.
    Endocr J; 2021 Jan 28; 68(1):17-29. PubMed ID: 32863282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.